Idorsia's Daridorexant and Patent Landscape
Idorsia Pharmaceuticals' insomnia treatment, daridorexant, is protected by a portfolio of patents. These patents are crucial for maintaining market exclusivity and preventing generic competition. DrugPatentWatch.com tracks the patent status of drugs like daridorexant [1].
When Does Daridorexant's Key Patent Protection End?
The primary patent protecting daridorexant is U.S. Patent No. 10,947,178, which is scheduled to expire in 2037 [1]. This patent covers the composition of matter for daridorexant. However, other patents related to its manufacturing processes and methods of use may have different expiration dates [1].
Can Generic Versions of Daridorexant Be Made Before Patent Expiry?
Generally, generic manufacturers cannot produce daridorexant until the relevant patents expire. Challenges to these patents can occur, potentially leading to earlier market entry for generics if the challenges are successful.
What Other Patents Cover Daridorexant?
Beyond the composition of matter patent, Idorsia likely holds patents covering specific crystalline forms, formulations, and manufacturing methods for daridorexant. These secondary patents can extend market exclusivity even after the primary patent expires. DrugPatentWatch.com provides detailed information on all patents associated with a drug [1].
How Do Patents Affect Daridorexant's Price and Availability?
Patents grant pharmaceutical companies a period of market exclusivity, during which they can set the price without direct competition. Once patents expire, generic versions can enter the market, typically leading to significant price reductions and increased availability.
Are There Any Patent Disputes Involving Daridorexant?
While specific patent disputes for daridorexant are not detailed in the provided information, it is common for patents protecting new drugs to face legal challenges from generic manufacturers seeking to enter the market earlier. These challenges often involve arguments about patent validity or inventorship.
What is Daridorexant and How Does It Work?
Daridorexant, sold under the brand name Quviviq, is a dual orexin receptor antagonist used to treat insomnia. It works by blocking the action of orexin, a neurotransmitter that promotes wakefulness, thereby helping individuals fall asleep and stay asleep [2].
When Was Daridorexant Approved?
Daridorexant received U.S. Food and Drug Administration (FDA) approval in January 2022 for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2].
What are the Potential Side Effects of Daridorexant?
Common side effects of daridorexant include somnolence, headache, fatigue, and nausea. Patients are advised to avoid driving or engaging in other activities requiring full alertness after taking the medication until they know how it affects them [2].
Who are Idorsia's Competitors in the Insomnia Market?
The insomnia market includes various other medications with different mechanisms of action. Competitors to daridorexant include other orexin receptor antagonists, as well as benzodiazepines, non-benzodiazepine hypnotics, and melatonin receptor agonists.
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Daridorexant Patents. Retrieved from https://drugpatentwatch.com/
[2] U.S. Food & Drug Administration. (2022, January 7). FDA Approves New Medication for Insomnia. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-insomnia